{"organizations": [], "uuid": "71abc0e458191131356ab3e37346bed8e4d2417d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180523.html", "section_title": "Archive News &amp; Video for Wednesday, 23 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-clementias-treatment-with-palovaro/brief-clementias-treatment-with-palovarotene-significantly-reduces-new-bone-growth-in-patients-with-fop-idUSFWN1SU0DO", "country": "US", "domain_rank": 408, "title": "BRIEF-Clementia's Treatment With Palovarotene Significantly Reduces New Bone Growth In Patients With FOP", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.559, "site_type": "news", "published": "2018-05-23T19:06:00.000+03:00", "replies_count": 0, "uuid": "71abc0e458191131356ab3e37346bed8e4d2417d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-clementias-treatment-with-palovaro/brief-clementias-treatment-with-palovarotene-significantly-reduces-new-bone-growth-in-patients-with-fop-idUSFWN1SU0DO", "ord_in_thread": 0, "title": "BRIEF-Clementia's Treatment With Palovarotene Significantly Reduces New Bone Growth In Patients With FOP", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "clementia pharmaceuticals inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 23 (Reuters) - Clementia Pharmaceuticals Inc:\n* CLEMENTIA REPORTS POSITIVE PHASE 2 PART B DATA SHOWING TREATMENT WITH PALOVAROTENE SIGNIFICANTLY REDUCES NEW BONE GROWTH IN PATIENTS WITH FOP\n* PHASE 2 PART B DATA SHOW EVALUABLE PATIENTS WITH NO NEW BONE AT 12 WEEKS HAD NO NEW BONE AT 12 MONTHS\n* STATISTICALLY SIGNIFICANT 91% REDUCTION OF NEW HO AT FLARE-UP SITES AT 12 WEEKS; 65% REDUCTION OF NEW HO AT 12-MONTH WBCT SCAN IN PHASE 2 DATA\n* PALOVAROTENE GENERALLY WELL-TOLERATED IN TRIAL, CONSISTENT WITH EXPERIENCE ACROSS PALOVAROTENE CLINICAL STUDIES\n* RECENTLY SURPASSED ENROLLMENT OF FIRST 35 PATIENTS IN OUR PHASE 3 MOVE TRIAL, ON TRACK TO COMPLETE STUDY ENROLLMENT BY YEAR END\n* ON TRACK TO REPORT FIRST INTERIM ANALYSIS FOR MOVE TRIAL IN MID-2019 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-23T19:06:00.000+03:00", "crawled": "2018-05-24T20:16:49.005+03:00", "highlightTitle": ""}